text: <unk>  is a tyrosine kinase nhibitor that is FDA approved for the treatment of non small cell lung cancer (NSCLC), pancreatic cancer.   Common adverse reactions include edema，alopecia，pruritus，rash，decreased weight，abdominal pain，diarrhea，flatulence, indigestion，inflammatory disease of mucous membrane，loss of appetite，nausea，vomiting, hyperbilirubinemia, increased liver enzymes，infectious disease，bone pain，myalgia，headache，conjunctivitis, keratoconjunctivitis sicca，anxiety，depression，cough，dyspnea，fatigue, fever..
option_0: Erlotinib
option_1: Nilotinib
option_2: Afatinib
option_3: Axitinib
option_4: Sunitinib
option_5: Crizotinib
option_6: Gefitinib
option_7: Neratinib